This algorithm and implementation guide are intended to help clinicians at the point of care initiate oral antiviral treatment for COVID-19. Based on efficacy data, nirmatrelvir/ritonavir (NMV/r) is the preferred agent, followed by molnupiravir.
These tools were created by USAID Implementing partners EpIC, RISE, STAR-UCSF.